Browse
Search for other papers by Xianhui Ruan in
Google Scholar
PubMed
Search for other papers by Xianle Shi in
Google Scholar
PubMed
Search for other papers by Qiman Dong in
Google Scholar
PubMed
Search for other papers by Yang Yu in
Google Scholar
PubMed
Search for other papers by Xiukun Hou in
Google Scholar
PubMed
Search for other papers by Xinhao Song in
Google Scholar
PubMed
Search for other papers by Xi Wei in
Google Scholar
PubMed
Search for other papers by Lingyi Chen in
Google Scholar
PubMed
Search for other papers by Ming Gao in
Google Scholar
PubMed
There is no effective treatment for patients with poorly differentiated papillary thyroid cancer or anaplastic thyroid cancer (ATC). Anlotinib, a multi-kinase inhibitor, has already shown antitumor effects in various types of carcinoma in a phase I clinical trial. In this study, we aimed to better understand the effect and efficacy of anlotinib against thyroid carcinoma cells in vitro and in vivo. We found that anlotinib inhibits the cell viability of papillary thyroid cancer and ATC cell lines, likely due to abnormal spindle assembly, G2/M arrest, and activation of TP53 upon anlotinib treatment. Moreover, anlotinib suppresses the migration of thyroid cancer cells in vitro and the growth of xenograft thyroid tumors in mice. Our data demonstrate that anlotinib has significant anticancer activity in thyroid cancer, and potentially offers an effective therapeutic strategy for patients of advanced thyroid cancer type.
Search for other papers by Simon Linder in
Google Scholar
PubMed
Search for other papers by Henk G van der Poel in
Google Scholar
PubMed
Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Search for other papers by Andries M Bergman in
Google Scholar
PubMed
Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands
Search for other papers by Wilbert Zwart in
Google Scholar
PubMed
Search for other papers by Stefan Prekovic in
Google Scholar
PubMed
The androgen receptor drives the growth of metastatic castration-resistant prostate cancer. This has led to the development of multiple novel drugs targeting this hormone-regulated transcription factor, such as enzalutamide – a potent androgen receptor antagonist. Despite the plethora of possible treatment options, the absolute survival benefit of each treatment separately is limited to a few months. Therefore, current research efforts are directed to determine the optimal sequence of therapies, discover novel drugs effective in metastatic castration-resistant prostate cancer and define patient subpopulations that ultimately benefit from these treatments. Molecular studies provide evidence on which pathways mediate treatment resistance and may lead to improved treatment for metastatic castration-resistant prostate cancer. This review provides, firstly a concise overview of the clinical development, use and effectiveness of enzalutamide in the treatment of advanced prostate cancer, secondly it describes translational research addressing enzalutamide response vs resistance and lastly highlights novel potential treatment strategies in the enzalutamide-resistant setting.
Search for other papers by Milena Doroszko in
Google Scholar
PubMed
Search for other papers by Marcin Chrusciel in
Google Scholar
PubMed
Search for other papers by Joanna Stelmaszewska in
Google Scholar
PubMed
Search for other papers by Tomasz Slezak in
Google Scholar
PubMed
Search for other papers by Slawomir Anisimowicz in
Google Scholar
PubMed
Search for other papers by Ursula Plöckinger in
Google Scholar
PubMed
Department of Clinical Endocrinology, Charité Campus Mitte, Charité University Medicine Berlin, Berlin, Germany
Search for other papers by Marcus Quinkler in
Google Scholar
PubMed
Search for other papers by Marco Bonomi in
Google Scholar
PubMed
Search for other papers by Slawomir Wolczynski in
Google Scholar
PubMed
Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, U.K.
Search for other papers by Ilpo Huhtaniemi in
Google Scholar
PubMed
Department of Pediatrics, Turku University Hospital, Turku, Finland
Search for other papers by Jorma Toppari in
Google Scholar
PubMed
Department of Reproduction and Gynecological Endocrinology, Medical University of Bialystok, Bialystok, Poland
Search for other papers by Nafis A Rahman in
Google Scholar
PubMed
Aberrantly expressed G protein-coupled receptors in tumors are considered as potential therapeutic targets. We analyzed the expressions of receptors of gonadotropin-releasing hormone (GNRHR), luteinizing hormone/chorionic gonadotropin (LHCGR) and follicle-stimulating hormone (FSHR) in human adrenocortical carcinomas and assessed their response to GnRH antagonist therapy. We further studied the effects of the GnRH antagonist cetrorelix acetate (CTX) on cultured adrenocortical tumor (ACT) cells (mouse Cα1 and Y-1, and human H295R), and in vivo in transgenic mice (SV40 T-antigen expression under inhibin α promoter) bearing Lhcgr and Gnrhr in ACT. Both models were treated with control (CT), CTX, human chorionic gonadotropin (hCG) or CTX+hCG, and their growth and transcriptional changes were analyzed. In situ hybridization and qPCR analysis of human adrenocortical carcinomas (n = 11–13) showed expression of GNRHR in 54/73%, LHCGR in 77/100% and FSHR in 0%, respectively. CTX treatment in vitro decreased cell viability and proliferation, and increased caspase 3/7 activity in all treated cells. In vivo, CTX and CTX+hCG (but not hCG alone) decreased ACT weights and serum LH and progesterone concentrations. CTX treatment downregulated the tumor markers Lhcgr and Gata4. Upregulated genes included Grb10, Rerg, Nfatc and Gnas, all recently found to be abundantly expressed in healthy adrenal vs ACT. Our data suggest that CTX treatment may improve the therapy of human adrenocortical carcinomas by direct action on GNRHR-positive cancer cells inducing apoptosis and/or reducing gonadotropin release, directing tumor cells towards a healthy adrenal gene expression profile.
Department of Endocrinology, King’s College Hospital NHS Foundation Trust, London, UK
Search for other papers by Paraskevi Xekouki in
Google Scholar
PubMed
Department of Endocrinology and Diabetes, King’s College London, London, UK
Search for other papers by Emily J Lodge in
Google Scholar
PubMed
Search for other papers by Jakob Matschke in
Google Scholar
PubMed
Department of Internal Medicine III, Carl Gustav Carus Medical School, Technical University of Dresden, Dresden, Germany
Search for other papers by Alice Santambrogio in
Google Scholar
PubMed
Histopathology Department, Great Ormond Street Hospital NHS Trust, London, UK
Search for other papers by John R Apps in
Google Scholar
PubMed
Search for other papers by Ariane Sharif in
Google Scholar
PubMed
Histopathology Department, Great Ormond Street Hospital NHS Trust, London, UK
Search for other papers by Thomas S Jacques in
Google Scholar
PubMed
Search for other papers by Simon Aylwin in
Google Scholar
PubMed
Search for other papers by Vincent Prevot in
Google Scholar
PubMed
Search for other papers by Ran Li in
Google Scholar
PubMed
Search for other papers by Jörg Flitsch in
Google Scholar
PubMed
Department of Internal Medicine III, Carl Gustav Carus Medical School, Technical University of Dresden, Dresden, Germany
Search for other papers by Stefan R Bornstein in
Google Scholar
PubMed
Search for other papers by Marily Theodoropoulou in
Google Scholar
PubMed
Department of Internal Medicine III, Carl Gustav Carus Medical School, Technical University of Dresden, Dresden, Germany
Search for other papers by Cynthia L Andoniadou in
Google Scholar
PubMed
Tumours of the anterior pituitary can manifest from all endocrine cell types but the mechanisms for determining their specification are not known. The Hippo kinase cascade is a crucial signalling pathway regulating growth and cell fate in numerous organs. There is mounting evidence implicating this in tumour formation, where it is emerging as an anti-cancer target. We previously demonstrated activity of the Hippo kinase cascade in the mouse pituitary and nuclear association of its effectors YAP/TAZ with SOX2-expressing pituitary stem cells. Here, we sought to investigate whether these components are expressed in the human pituitary and if they are deregulated in human pituitary tumours. Analysis of pathway components by immunofluorescence reveals pathway activity during normal human pituitary development and in the adult gland. Poorly differentiated pituitary tumours (null-cell adenomas, adamantinomatous craniopharyngiomas (ACPs) and papillary craniopharyngiomas (PCPs)), displayed enhanced expression of pathway effectors YAP/TAZ. In contrast, differentiated adenomas displayed lower or absent levels. Knockdown of the kinase-encoding Lats1 in GH3 rat mammosomatotropinoma cells suppressed Prl and Gh promoter activity following an increase in YAP/TAZ levels. In conclusion, we have demonstrated activity of the Hippo kinase cascade in the human pituitary and association of high YAP/TAZ with repression of the differentiated state both in vitro and in vivo. Characterisation of this pathway in pituitary tumours is of potential prognostic value, opening up putative avenues for treatments.
Department of Endocrinology, St Bartholomew’s Hospital, Barts Health NHS Trust, London, UK
Search for other papers by Samuel M O’Toole in
Google Scholar
PubMed
Search for other papers by David S Watson in
Google Scholar
PubMed
Search for other papers by Tatiana V Novoselova in
Google Scholar
PubMed
Search for other papers by Lisa E L Romano in
Google Scholar
PubMed
Search for other papers by Peter J King in
Google Scholar
PubMed
Search for other papers by Teisha Y Bradshaw in
Google Scholar
PubMed
Search for other papers by Clare L Thompson in
Google Scholar
PubMed
Search for other papers by Martin M Knight in
Google Scholar
PubMed
Search for other papers by Tyson V Sharp in
Google Scholar
PubMed
Search for other papers by Michael R Barnes in
Google Scholar
PubMed
Department of Endocrinology, St Bartholomew’s Hospital, Barts Health NHS Trust, London, UK
Department of Diabetes and Endocrinology, University College London Hospital, London, UK
Search for other papers by Umasuthan Srirangalingam in
Google Scholar
PubMed
Search for other papers by William M Drake in
Google Scholar
PubMed
Search for other papers by J Paul Chapple in
Google Scholar
PubMed
Primary cilia are sensory organelles involved in regulation of cellular signaling. Cilia loss is frequently observed in tumors; yet, the responsible mechanisms and consequences for tumorigenesis remain unclear. We demonstrate that cilia structure and function is disrupted in human pheochromocytomas – endocrine tumors of the adrenal medulla. This is concomitant with transcriptional changes within cilia-mediated signaling pathways that are associated with tumorigenesis generally and pheochromocytomas specifically. Importantly, cilia loss was most dramatic in patients with germline mutations in the pseudohypoxia-linked genes SDHx and VHL. Using a pheochromocytoma cell line derived from rat, we show that hypoxia and oncometabolite-induced pseudohypoxia are key drivers of cilia loss and identify that this is dependent on activation of an Aurora-A/HDAC6 cilia resorption pathway. We also show cilia loss drives dramatic transcriptional changes associated with proliferation and tumorigenesis. Our data provide evidence for primary cilia dysfunction contributing to pathogenesis of pheochromocytoma by a hypoxic/pseudohypoxic mechanism and implicates oncometabolites as ciliary regulators. This is important as pheochromocytomas can cause mortality by mechanisms including catecholamine production and malignant transformation, while hypoxia is a general feature of solid tumors. Moreover, pseudohypoxia-induced cilia resorption can be pharmacologically inhibited, suggesting potential for therapeutic intervention.
Search for other papers by Martin Ullrich in
Google Scholar
PubMed
Technische Universität Dresden, School of Medicine, Faculty of Medicine Carl Gustav Carus, Dresden, Germany
Search for other papers by Josephine Liers in
Google Scholar
PubMed
Search for other papers by Mirko Peitzsch in
Google Scholar
PubMed
Search for other papers by Anja Feldmann in
Google Scholar
PubMed
Search for other papers by Ralf Bergmann in
Google Scholar
PubMed
Search for other papers by Ulrich Sommer in
Google Scholar
PubMed
Technische Universität Dresden, University Hospital Carl Gustav Carus, Institute of Clinical Chemistry and Laboratory Medicine, Dresden, Germany
Search for other papers by Susan Richter in
Google Scholar
PubMed
Department of Internal Medicine III, Technische Universität Dresden, University Hospital Carl Gustav Carus, Dresden, Germany
Search for other papers by Stefan R Bornstein in
Google Scholar
PubMed
Department of Radioimmunology, Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany
Technische Universität Dresden, University Hospital Carl Gustav Carus, Universitäts Krebs Centrum (UCC), Tumorimmunology, Dresden, Germany
Technische Universität Dresden, National Center for Tumor Diseases (NCT), Dresden, Germany
Search for other papers by Michael Bachmann in
Google Scholar
PubMed
Technische Universität Dresden, University Hospital Carl Gustav Carus, Institute of Clinical Chemistry and Laboratory Medicine, Dresden, Germany
Department of Internal Medicine III, Technische Universität Dresden, University Hospital Carl Gustav Carus, Dresden, Germany
Search for other papers by Graeme Eisenhofer in
Google Scholar
PubMed
Search for other papers by Christian G Ziegler in
Google Scholar
PubMed
Technische Universität Dresden, School of Science, Faculty of Chemistry and Food Chemistry, Dresden, Germany
Search for other papers by Jens Pietzsch in
Google Scholar
PubMed
Somatostatin receptor-targeting endoradiotherapy offers potential for treating metastatic pheochromocytomas and paragangliomas, an approach likely to benefit from combination radiosensitization therapy. To provide reliable preclinical in vivo models of metastatic disease, this study characterized the metastatic spread of luciferase-expressing mouse pheochromocytoma (MPC) cells in mouse strains with different immunologic conditions. Bioluminescence imaging showed that, in contrast to subcutaneous non-metastatic engraftment of luciferase-expressing MPC cells in NMRI-nude mice, intravenous cell injection provided only suboptimal metastatic spread in both NMRI-nude mice and hairless SCID (SHO) mice. Treatment of NMRI-nude mice with anti-Asialo GM1 serum enhanced metastatic spread due to substantial depletion of natural killer (NK) cells. However, reproducible metastatic spread was only observed in NK cell-defective SCID/beige mice and in hairless immunocompetent SKH1 mice bearing disseminated or liver metastases, respectively. Liquid chromatography tandem mass spectrometry of urine samples showed that subcutaneous and metastasized tumor models exhibit comparable renal monoamine excretion profiles characterized by increasing urinary dopamine, 3-methoxytyramine, norepinephrine and normetanephrine. Metastases-related epinephrine and metanephrine were only detectable in SCID/beige mice. Positron emission tomography and immunohistochemistry revealed that all metastases maintained somatostatin receptor-specific radiotracer uptake and immunoreactivity, respectively. In conclusion, we demonstrate that intravenous injection of luciferase-expressing MPC cells into SCID/beige and SKH1 mice provides reproducible and clinically relevant spread of catecholamine-producing and somatostatin receptor-positive metastases. These standardized preclinical models allow for precise monitoring of disease progression and should facilitate further investigations on theranostic approaches against metastatic pheochromocytomas and paragangliomas.
Search for other papers by Jonathan W Nyce in
Google Scholar
PubMed
The activation of TP53 is well known to exert tumor suppressive effects. We have detected a primate-specific adrenal androgen-mediated tumor suppression system in which circulating DHEAS is converted to DHEA specifically in cells in which TP53 has been inactivated. DHEA is an uncompetitive inhibitor of glucose-6-phosphate dehydrogenase (G6PD), an enzyme indispensable for maintaining reactive oxygen species within limits survivable by the cell. Uncompetitive inhibition is otherwise unknown in natural systems because it becomes irreversible in the presence of high concentrations of substrate and inhibitor. In addition to primate-specific circulating DHEAS, a unique, primate-specific sequence motif that disables an activating regulatory site in the glucose-6-phosphatase (G6PC) promoter was also required to enable function of this previously unrecognized tumor suppression system. In human somatic cells, loss of TP53 thus triggers activation of DHEAS transport proteins and steroid sulfatase, which converts circulating DHEAS into intracellular DHEA, and hexokinase which increases glucose-6-phosphate substrate concentration. The triggering of these enzymes in the TP53-affected cell combines with the primate-specific G6PC promoter sequence motif that enables G6P substrate accumulation, driving uncompetitive inhibition of G6PD to irreversibility and ROS-mediated cell death. By this catastrophic ‘kill switch’ mechanism, TP53 mutations are effectively prevented from initiating tumorigenesis in the somatic cells of humans, the primate with the highest peak levels of circulating DHEAS. TP53 mutations in human tumors therefore represent fossils of kill switch failure resulting from an age-related decline in circulating DHEAS, a potentially reversible artifact of hominid evolution.
Division of Molecular Pathology, The Institute of Cancer Research, London, UK
Search for other papers by Abigail Read in
Google Scholar
PubMed
Division of Molecular Pathology, The Institute of Cancer Research, London, UK
Search for other papers by Rachael Natrajan in
Google Scholar
PubMed
Breast cancer is known to be a heterogeneous disease driven by a large repertoire of molecular abnormalities, which contribute to its diverse clinical behaviour. Despite the success of targeted therapy approaches for breast cancer patient management, there is still a lack of the molecular understanding of aggressive forms of the disease and clinical management of these patients remains difficult. The advent of high-throughput sequencing technologies has paved the way for a more complete understanding of the molecular make-up of the breast cancer genome. As such, it is becoming apparent that disruption of canonical splicing within breast cancer governs its clinical progression. In this review, we discuss the role of dysregulation of spliceosomal component genes and associated factors in the progression of breast cancer, their role in therapy resistance and the use of quantitative isoform expression as potential prognostic and predictive biomarkers with a particular focus on oestrogen receptor-positive breast cancer.
Search for other papers by J Crona in
Google Scholar
PubMed
Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, UniversitätsSpital Zürich, Zürich, Switzerland
Search for other papers by F Beuschlein in
Google Scholar
PubMed
Search for other papers by K Pacak in
Google Scholar
PubMed
Search for other papers by B Skogseid in
Google Scholar
PubMed
This review aims to provide clinicians and researchers with a condensed update on the most important studies in the field during 2017. We present the academic output measured by active clinical trials and peer-reviewed published manuscripts. The most important and contributory manuscripts were summarized for each diagnostic entity, with a particular focus on manuscripts that describe translational research that have the potential to improve clinical care. Finally, we highlight the importance of collaborations in adrenal tumor research, which allowed for these recent advances and provide structures for future success in this scientific field.
Search for other papers by Claudia Tulotta in
Google Scholar
PubMed
Search for other papers by Penelope Ottewell in
Google Scholar
PubMed
Approximately 75% of patients with late-stage breast cancer will develop bone metastasis. This condition is currently considered incurable and patients’ life expectancy is limited to 2–3 years following diagnosis of bone involvement. Interleukin (IL)-1B is a pro-inflammatory cytokine whose expression in primary tumours has been identified as a potential biomarker for predicting breast cancer patients at increased risk for developing bone metastasis. In this review, we discuss how IL-1B from both the tumour cells and the tumour microenvironment influence growth of primary breast tumours, dissemination into the bone metastatic niche and proliferation into overt metastases. Recent evidence indicates that targeting IL-1B signalling may provide promising new treatments that can hold tumour cells in a dormant state within bone thus preventing formation of overt bone metastases.